Alkermes plc(ALKS) Stock Research - Grey Stern Research

Alkermes plc (ALKS) Stock Analysis

$27.83 (0.61%)

ALKS Financial Performance


Use the table below to view Alkermes plc's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $26.56 -
52 Week Low $22.01 -
52 Week High $32.88 -
Market Cap $4.4 Billion 4/15
Gross Margin 84% 5/15
Profit Margin 23% 1/15
EBITDA margin 29% 4/15
Q2 - 2024 Revenue $399.1 Million 2/15
Q2 - 2024 Earnings $91.4 Million 1/15
Q2 - 2024 Free Cash Flow $138.9 Million 1/15
Trailing 4 Quarters Revenue $1.5 Billion 3/15
Trailing 4 Quarters Earnings $336.5 Million 3/15
Quarterly Earnings Growth -61% 12/15
Annual Earnings Growth 202% 4/15
Quarterly Revenue Growth -35% 14/15
Annual Revenue Growth 2% 10/15
Cash On Hand $535.2 Million 2/15
Short Term Debt $9.0 Million 5/15
Long Term Debt $286.5 Million 7/15

Alkermes plc Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Alkermes plc's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 13.00 8/15
PS 2.90 9/15
PB 3.41 7/15
PC 8.17 10/15
Liabilities to Equity 0.72 8/15
ROA 0.15 2/15
ROE 0.26 2/15
Current Ratio 2.39 7/15
Quick Ratio 0.95 5/15
Long Term Debt to Equity 0.22 10/15
Debt to Equity 0.29 9/15
Burn Rate -6.89 11/15
Cash to Cap 0.12 6/15
CCR 1.52 5/15
EV to EBITDA 36.09 8/15
EV to Revenue 2.79 9/15

Company Details

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CEO: Mr. Richard Pops

Website: https://www.alkermes.com

Address: Connaught HSE, 1 Burlington Road DUBLIN, DUBLIN

Exchange: NASDAQ Global Select

Industry: Biotechnology

Alkermes plc Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Alkermes plc. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Prestige Consumer Healthcare Inc. PBH $3.7 Billion
Dynavax Technologies Corporation DVAX $1.5 Billion
Pacira BioSciences, Inc. PCRX $604.7 Million
Neurocrine Biosciences, Inc. NBIX $12.3 Billion
Ironwood Pharmaceuticals, Inc. IRWD $730.0 Million
Collegium Pharmaceutical, Inc. COLL $1.2 Billion
Eagle Pharmaceuticals, Inc. EGRX $54.9 Million
Dr. Reddy's Laboratories Limited RDY $13.3 Billion
Intra-Cellular Therapies, Inc. ITCI $8.0 Billion
ANI Pharmaceuticals, Inc. ANIP $1.2 Billion
Amphastar Pharmaceuticals, Inc. AMPH $2.4 Billion
Phibro Animal Health Corporation PAHC $890.7 Million
Deciphera Pharmaceuticals, Inc. DCPH $2.2 Billion
Evolus, Inc. EOLS $1.1 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ALKS Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 399.1 Million $91.4 Million
Q1 2024 $ 350.4 Million $36.8 Million
Q4 2023 $ 377.5 Million $160.6 Million
Q3 2023 $ 380.9 Million $47.8 Million
Q2 2023 $ 617.4 Million $237.1 Million
Q1 2023 $ 287.6 Million -$41.8 Million
Q4 2022 $ 304.7 Million -$28.3 Million
Q3 2022 $ 252.4 Million -$64.0 Million

View All

ALKS Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $535.2 Million $2.2 Billion $368.0 Million $1.3 Billion
Q1 2024 $420.8 Million $2.1 Billion $370.1 Million $1.3 Billion
Q4 2023 $461,000 $461,000 $0 $0
Q3 2023 $647.7 Million $2.3 Billion $291.4 Million $1.4 Billion
Q2 2023 $665.8 Million $2.2 Billion $292.0 Million $1.3 Billion
Q1 2023 $321.4 Million $1.9 Billion $292.6 Million $1.0 Billion
Q4 2022 $292.5 Million $2.0 Billion $293.3 Million $1.0 Billion
Q3 2022 $264.0 Million $1.9 Billion $405.4 Million $1.0 Billion

View All

ALKS Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $138.9 Million -$7.1 Million $114.4 Million
Q1 2024 $12.8 Million -$8.3 Million -$36.7 Million
Q4 2023 $112,800 $0 $112,800
Q3 2023 $85.3 Million -$14.5 Million -$18.1 Million
Q2 2023 $206.0 Million -$9.7 Million $344.4 Million
Q1 2023 -$28.2 Million -$6.9 Million $28.9 Million
Q4 2022 -$9.0 Million -$10.0 Million $28.5 Million
Q3 2022 $21.1 Million $20.4 Million $9.3 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions